Over the course of the projection period, the LATAM fabry disease market is anticipated to rise due to the Brazilian Society of Nephrology's development of a consensus document for the diagnosis of the condition. In order to standardise recommendations related to kidney involvement in fabry disease in the areas of diagnosis, screening, and treatment of adult and paediatric patients, the Committee for Rare Diseases of the Brazilian Society of Nephrology, for example, developed a consensus document, as reported in data published in June 2022 by Brazilian Journal of Nephrology. In order to help doctors and patients understand how the treatment for fabry illness is working, a consensus statement has been developed. The expansion of the LATAM fabry disease market is anticipated to be fueled by key players expanding their drug discovery research and development efforts throughout the course of the forecast period. Academic research into the conditions causes and therapies is expected to rise over the course of the forecast period, propelling the LATAM fabry disease market.
According to Coherent Market Insights, The LATAM Fabry Disease Market is projected to reach US$ 81.330 Mn in 2022 and is anticipated to grow at a 6.7% CAGR from 2022 to 2030.
Major Players in the LATAM Fabry Disease Industry:
1. Novartis
The company was founded in March 1996 and has its main offices in Basel, Switzerland, and Cambridge, Massachusetts, in the United States. Novartis provides coverage for all types of medications, including authorization, over-the-counter, immunisations, diagnostics, eyewear, and veterinary care. Through its firms, Novartis engages in a number of direct activities, including managing, advertising, operations, and research.
2. Teva Pharmaceutical Industries Ltd.
The corporation was founded in 1901 and has its headquarters in Tel Aviv, Israel. Although its primary area of expertise is in generic drugs, it also has some additional business interests in active pharmaceutical ingredients and, to a lesser extent, patented drugs. The aggressive climate targets set by Teva will have received external validation on January 19, 2023, thanks to the Science Based Targets programme (SBTi). Teva said on January 9th, 2023 that the federal opioids deal will proceed after receiving strong support from the states.
3. Pfizer Inc.,
The corporation was founded in 1849, and its corporate headquarters are located in Manhattan, New York City. Pfizer works to advance the disciplines of immunology, cancer, the heart, endocrinology, and neurology through pharmaceutical and vaccine research & development. The company successfully purchased the calcitonin gene-related peptide programmes from Biohaven Pharma in October 2022. In April 2021, Pfizer acquired Amplyx Pharmaceuticals, along with the antifungal medication fosmanogepix. (APX001).
4. GlaxoSmithKline plc,
The company was established in 2000, and London, England serves as its headquarters. GSK creates medications for conditions like diabetes, cancer, worms, and mental health. Three unsolicited proposals to purchase Unilever's Consumer Healthcare sector were received by the company in January 2022, according to the report. In November 2022, GSK published upbeat Phase IIa research findings for a brand-new, ground-breaking prospective therapy for tuberculosis patients.
5.Takeda Pharmaceuticals U.S.A., Inc,
The company was founded in 1781 and is based in Massachusetts, in the United States. Oncology, uncommon diseases, neurology, gastroenterology, particle medicine, and immunisations are some of the company's key areas of focus. In February 2023, Takeda completed the acquisition of Nimbus Therapeutics' TYK2 Programme Subsidiary. To develop a first-of-its-kind treatment for celiac disease, Takeda struck a partnership and licencing agreement with Zedira and Dr. Falk Pharma in October 2022.
6. Moderna Therapeutics Inc
The company was started in 2010 and is based in Massachusetts, United States. The company's main areas of interest include the development of messenger RNA vaccines and treatments. For the treatment of infectious, immuno-oncological, and cardiovascular disorders, Moderna creates mRNA medications. Moderna's first acquisition was OriCiro Genomics, a Japanese producer of tools for genetic engineering, in 2023.
7. Resverlogix
The business was founded in 2000 and is based in Calgary, Canada. A biotechnology business called Resverlogix Corp. is dedicated to creating treatments for unmet medical needs. The company focuses on fibrotic disorders, cancer, and cardiovascular disease. Resverlogix Corp. is a clinical biotechnology firm in its late stages that is committed on enhancing the quality of life for people with chronic illnesses.
Definition: The Galactosidase Alpha (GLA) gene deficiency in the body causes the rare genetic illness known as Fabry disease. The alpha-galactosidase A enzyme is deficient due to a gene deficiency.
